JAK2 and plasma cell myeloma: Ramakrishnan, V et al studied the effects of TG101209 on CD45 positive myeloma cell lines and primary plasma cells from myeloma patient, and confirmed that the induction of cytotoxicity of TG101209 accompanied by inhibition of cell cycle progression and induction of apoptosis, in which the mechanism of action of TG101209 involved in down regulation of p-JAK2, p-STAT3 and Bcl-xl levels [14].